Modified release studies on the new antitubercular compound (1,1’-[4,4’-[tricyclo[184.108.40.206.3,7]decane-1,3-diyl]bis(phenoxyethyl)]dipyrrolidine, bis-hydrochloride salt from solid pharmaceutical formulations.
M. Vlachou*, A. Siamidi, P. Ladia, K. Anastasiou, I. Papanastasiou
The modified release of a new, potent antitubercular agent (compound 1), from tablets and hard gelatin capsules, into gastrointestinal-like fluids, was probed. Albeit its high lipophilicity, compared to its congeneric derivative, SQ109, the dissolution profile of 1 was found to be in alignment with the release characteristics necessary for antitubercular action (relatively fast initial release followed by a gradient). The excipients used to achieve this dissolution pattern were combinations of sodium alginate, lactose monohydrate, and polyvinylpyrrolidone (PVP).
The Migraine Known as Supplier Audits and Some Basic Remedies
Biocore Publishing Group
All Published work is licensed under a Creative Commons Attribution 4.0 International License.